Status:
COMPLETED
Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice
Lead Sponsor:
Pfizer
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without per...
Detailed Description
t
Eligibility Criteria
Inclusion
- Male or female patients of 18 years or more presenting with chest pain will be potentially eligible for inclusion in the study if they satisfy the criteria for unstable coronary artery disease per the investigator's routine practice and have received at least one injection of Fragmin (dalteparin sodium) as part of routine clinical practice and is expected to be treated conservatively (without PCI or CABG within 48 hours) during the index hospitalization.
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion
- Patients who are contraindicated to receive this agent per the local approved prescribing information.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
618 Patients enrolled
Trial Details
Trial ID
NCT00922766
Start Date
May 1 2009
End Date
September 1 2010
Last Update
January 23 2012
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ahmedabad, Gujarat, India, 380 051
2
Pfizer Investigational Site
Surat, Gujarat, India, 395004
3
Pfizer Investigational Site
Hisar, Haryana, India, 125 001
4
Pfizer Investigational Site
Hisar, Haryana, India, 125005